Canada Bets $280M on Aspect Biosystems’ Bioprinted Tissue Therapeutics
Aspect Biosystems just landed $280M from the Canadian government to advance bioprinted cellular medicines — on top of a $115M Series B and a $2.7B Novo Nordisk deal.
Jeff Martin
Neutrolis Posts Positive Phase 1a Data for First-in-Class NET-Targeting Therapy
NTR-1011 is the first drug designed to dismantle neutrophil extracellular traps — and early safety data just cleared the way for lupus and RA patients.
A University Built a CAR-T Therapy From Scratch — And the FDA Said Yes
The University of Colorado Anschutz Gates Institute just became the first U.S. academic institution to take a fully in-house CAR-T from bench to IND — no pharma partner needed.
AvenCell Doses First Patient With Switchable Dual-Target CAR-T
AvenCell's AVC-203 is the first CRISPR-engineered allogeneic CAR-T with a switchable receptor to hit the clinic — and the timing couldn't be better.
FORE Biotherapeutics Completes the FDA Hat Trick for Plixorafenib in Brain Cancer
Plixorafenib just became the first targeted therapy to earn Breakthrough Therapy Designation in high-grade glioma — adding to Fast Track and Orphan Drug status.
Senti Biosciences Publishes Gene Circuit Science Behind Logic-Gated AML Therapy
The science behind programming immune cells with Boolean logic just got peer-reviewed — and the early clinical signals in AML are turning heads.
ARPA-H Awards Landmark Bio $18.3M to Solve the EV Therapeutics Manufacturing Problem
The US government is betting that extracellular vesicle therapies are bottlenecked by manufacturing, not science. $18.3M says they're right.
Korsana Biosciences Raises $380M, Merges With Cyclerion to Chase Alzheimer’s
From stealth to $555M raised in under two years. Korsana's brain-shuttled Alzheimer's antibody just got a public shell and a war chest.
Newleos Doses First Patient in Anti-Anxiety Drug Trial Designed to Replace Benzos
A GABA-selective anxiolytic that dodges sedation and addiction? Newleos just started dosing patients in the UK.
Ray Therapeutics Lands FDA RMAT Designation for Optogenetic Vision Therapy RTx-015
A single intravitreal injection that reprograms retinal cells to detect light. The FDA just gave it the fast lane.